DEQING, China—Shuwen Biotech Co. Ltd. and Bliss Biopharmaceutical Co. Ltd. have teamed up in a partnership agreement under which Shuwen will develop companion diagnostics for certain Bliss-developed oncology drug candidates, in addition to providing testing services for Bliss' clinical trials. Financial terms for the deal were not released.

“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” Dr. Ziping Wei, CEO of Bliss Biopharmaceutical, said in a press release.